Contrasting of Intercept Pharmaceuticals Inc. (ICPT) and Affimed N.V. (NASDAQ:AFMD)

We are contrasting Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) and Affimed N.V. (NASDAQ:AFMD) on their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intercept Pharmaceuticals Inc. 164.21M 21.19 332.51M -12.40 0.00
Affimed N.V. N/A 0.00 N/A -0.70 0.00

Demonstrates Intercept Pharmaceuticals Inc. and Affimed N.V. earnings per share, gross revenue and valuation.

Profitability

Table 2 provides us Intercept Pharmaceuticals Inc. and Affimed N.V.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Intercept Pharmaceuticals Inc. -202.49% -644.1% -65.2%
Affimed N.V. 0.00% -82.1% -63.5%

Risk & Volatility

Intercept Pharmaceuticals Inc. is 200.00% less volatile than S&P 500 due to its -1 beta. Affimed N.V.’s 265.00% more volatile than S&P 500 volatility due to the stock’s 3.65 beta.

Liquidity

The Current Ratio and a Quick Ratio of Intercept Pharmaceuticals Inc. are 6 and 6. Competitively, Affimed N.V. has 3.7 and 3.6 for Current and Quick Ratio. Intercept Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Affimed N.V.

Analyst Recommendations

The table given features the ratings and recommendations for Intercept Pharmaceuticals Inc. and Affimed N.V.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Intercept Pharmaceuticals Inc. 0 1 10 2.91
Affimed N.V. 0 0 2 3.00

Intercept Pharmaceuticals Inc. has an average target price of $166.4, and a 41.81% upside potential. Competitively Affimed N.V. has an average target price of $4.5, with potential upside of 31.58%. Based on the results given earlier, Intercept Pharmaceuticals Inc. is looking more favorable than Affimed N.V., analysts opinion.

Insider & Institutional Ownership

Roughly 65.1% of Intercept Pharmaceuticals Inc. shares are owned by institutional investors while 42.9% of Affimed N.V. are owned by institutional investors. Intercept Pharmaceuticals Inc.’s share owned by insiders are 23.3%. Competitively, Affimed N.V. has 16.7% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Intercept Pharmaceuticals Inc. -4.44% -7.4% -7.2% 39.22% 72.45% 81.43%
Affimed N.V. -20.09% -9.6% -25.42% 70.48% 88.42% 175.38%

For the past year Intercept Pharmaceuticals Inc. has weaker performance than Affimed N.V.

Summary

Affimed N.V. beats Intercept Pharmaceuticals Inc. on 7 of the 11 factors.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.